• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Nuvation Bio Inc. Class A Common Stock (NY:NUVB)

    5.460 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EST, Feb 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 314,395
    Open 5.460
    Bid (Size) 5.430 (1,300)
    Ask (Size) 5.570 (800)
    Prev. Close 5.460
    Today's Range 5.460 - 5.460
    52wk Range 1.540 - 9.750
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma
    From Nuvation Bio
    Via Business Wire
    News headline image
    Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
    From Nuvation Bio
    Via Business Wire

    Performance

    YTD
    -36.4%
    -36.4%
    1 Month
    -0.7%
    -0.7%
    3 Month
    -26.3%
    -26.3%
    6 Month
    +89.6%
    +89.6%
    1 Year
    +162.5%
    +162.5%

    More News

    Read More
    News headline image
    Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
    From Nuvation Bio and Eisai
    Via Business Wire
    Nuvation Bio Stock Logs Its Best Session Ever: Wall Street Turns Bullish On Lung Cancer Drug’s Blockbuster Debut ↗
    Via Stocktwits
    News headline image
    Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Nuvation Bio
    Via Business Wire
    News headline image
    Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
    From Nuvation Bio
    Via Business Wire
    News headline image
    Nuvation Bio to Participate in Upcoming Investor Conferences
    From Nuvation Bio
    Via Business Wire
    News headline image
    Earnings Scheduled For November 3, 2025 ↗
    Via Benzinga
    News headline image
    4 Analysts Assess Nuvation Bio: What You Need To Know ↗
    Via Benzinga
    News headline image
    Analyst Expectations For Nuvation Bio's Future ↗
    Via Benzinga
    News headline image
    Nuvation Bio (NUVB) Soars on IBTROZI's Blockbuster Launch and Stellar Q3 2025 Performance
    Via MarketMinute
    News headline image
    Which stocks are moving on Wednesday? ↗
    Via Chartmill
    News headline image
    Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Nuvation Bio (NUVB) Q3 2025 Earnings Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Nuvation Bio Inc.
    Via Business Wire
    News headline image
    Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Nuvation Bio to Participate in Upcoming Investor Conferences
    From Nuvation Bio
    Via Business Wire
    News headline image
    Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
    From Nuvation Bio
    Via Business Wire
    News headline image
    Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025
    From Nuvation Bio
    Via Business Wire
    News headline image
    Why Nuvation Bio Stock Is Skyrocketing Today ↗
    Via The Motley Fool
    News headline image
    United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday ↗
    Via Benzinga
    News headline image
    Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
    From Nuvation Bio
    Via Business Wire
    News headline image
    Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
    From Nuvation Bio
    Via Business Wire
    News headline image
    Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
    From Nuvation Bio
    Via Business Wire

    Frequently Asked Questions

    Is Nuvation Bio Inc. Class A Common Stock publicly traded?
    Yes, Nuvation Bio Inc. Class A Common Stock is publicly traded.
    What exchange does Nuvation Bio Inc. Class A Common Stock trade on?
    Nuvation Bio Inc. Class A Common Stock trades on the New York Stock Exchange
    What is the ticker symbol for Nuvation Bio Inc. Class A Common Stock?
    The ticker symbol for Nuvation Bio Inc. Class A Common Stock is NUVB on the New York Stock Exchange
    What is the current price of Nuvation Bio Inc. Class A Common Stock?
    The current price of Nuvation Bio Inc. Class A Common Stock is 5.460
    When was Nuvation Bio Inc. Class A Common Stock last traded?
    The last trade of Nuvation Bio Inc. Class A Common Stock was at 02/23/26 07:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.